StockData
Moderna, Inc. logo

Moderna, Inc.

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30508% above fair value
$196.79−10.01 (-4.84%)

Close on Nov 18, 2026Market cap $78.57BP/E –Yield –

Moderna Cases with job transfer or restriction by Year

Cases with job transfer or restriction (incidents)

Moderna Cases with job transfer or restriction: 2.00 incidents in FY2025, down 60.0% from a year earlier.

Latest, FY2025
2.00
Period ended Dec 31, 2025
Change on a year earlier
-60.0%
5.00 in FY2024
History
3 years
Since FY2023
Sources
1
2025 Impacting Human Health Report

Where the FY2025 figure comes from

“Job Transfer or Restriction(4) 1 5 2”

Source: 2025 Impacting Human Health Report ↗

Reported in Moderna 2025 Impacting Human Health Report.

annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCases with job transfer or restriction (incidents)Year on yearSource
FY2025Dec 31, 20252.00-60.0%2025 Impacting Human Health Report ↗
FY2024Dec 31, 20245.00+400.0%2025 Impacting Human Health Report ↗
FY2023Dec 31, 20231.00–2025 Impacting Human Health Report ↗

Cite this data

StockData. (2026). Moderna Cases with job transfer or restriction, annual FY2023–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/ehs-job-transfer

See every metric in the Moderna KPI table. Data updated Nov 3, 2026.

See a number that looks wrong?